156 related articles for article (PubMed ID: 23183505)
1. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
[TBL] [Abstract][Full Text] [Related]
2. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
3. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
4. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
7. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
8. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
[TBL] [Abstract][Full Text] [Related]
9. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy.
Couvert P; Chapman MJ; Carrié A
Pharmacogenomics; 2011 Feb; 12(2):137-9. PubMed ID: 21332305
[No Abstract] [Full Text] [Related]
12. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
14. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
[TBL] [Abstract][Full Text] [Related]
15. Impact of variants within seven candidate genes on statin treatment efficacy.
Vrablík M; Hubáček JA; Dlouhá D; Lánská V; Rynekrová J; Zlatohlávek L; Prusíková M; Ceška R; Adámková V
Physiol Res; 2012; 61(6):609-17. PubMed ID: 23098650
[TBL] [Abstract][Full Text] [Related]
16. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
18. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
19. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
20. Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study.
Sałacka A; Bińczak-Kuleta A; Kaczmarczyk M; Hornowska I; Safranow K; Clark JS
Bosn J Basic Med Sci; 2014 Aug; 14(3):144-9. PubMed ID: 25172973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
